What the Inflation Reduction Act Means for Your Drug Prices

The Inflation Reduction Act of 2022 is the most significant prescription drug pricing reform in decades. Here is what has changed so far, what is still coming, and whether it affects you.

Medicare Drug Price Negotiation: The Big Change

For the first time in the history of the Medicare program, the federal government now has the authority to directly negotiate prices for certain high-cost prescription drugs. Previously, Medicare was prohibited by law from negotiating drug prices, a policy that critics argued for years led to American seniors paying far more than necessary for their medications. The Inflation Reduction Act changed that, and the results are already taking effect.

The first round of negotiations covered ten drugs that represent some of the highest spending in Medicare Part D. These include Eliquis (apixaban) for blood clots, Jardiance (empagliflozin) for diabetes and heart failure, Xarelto (rivarelbaban) for blood clots, Januvia (sitagliptin) for diabetes, Farxiga (dapagliflozin) for diabetes and heart failure, Entresto (sacubitril/valsartan) for heart failure, Enbrel (etanercept) for autoimmune conditions, Imbruvica (ibrutinib) for blood cancers, Stelara (ustekinumab) for autoimmune conditions, and several insulin products including NovoLog and Fiasp. The negotiated prices for these first ten drugs took effect on January 1, 2026, and represent discounts of roughly 40% to 80% off previous list prices for Medicare beneficiaries.

The impact is substantial. Medicare estimates that the negotiated prices for just these ten drugs will save the program billions of dollars annually and reduce out-of-pocket costs for the millions of Medicare enrollees who take them. For individual patients, the savings can amount to hundreds or even thousands of dollars per year depending on the drug and their specific plan.

The $35 Insulin Cap

One of the most immediately felt provisions of the IRA is the $35 per month cap on insulin costs for Medicare Part D enrollees, which took effect in January 2023. Before this cap, many Medicare patients were paying $100, $200, or even $400 per month for insulin, depending on the type and their plan's coverage. The $35 cap applies to all covered insulin products regardless of the type or brand, including long-acting insulins like Lantus and Basaglar, rapid-acting insulins like Humalog and NovoLog, and mixed insulins.

This cap has been transformative for the roughly 3.3 million Medicare beneficiaries who use insulin. For a patient who was previously paying $200 per month, the cap saves them nearly $2,000 per year. The provision applies at the pharmacy counter, meaning patients see the lower price immediately without needing to file claims or wait for reimbursement.

It is worth noting that the $35 cap applies specifically to Medicare patients. Several major insulin manufacturers have independently capped their insulin list prices at or near $35 for all patients (Eli Lilly, Novo Nordisk, and Sanofi have all made such commitments), which means the practical benefit has extended beyond Medicare. However, the legal guarantee of the $35 price exists only for Medicare under the IRA.

The $2,000 Out-of-Pocket Cap for Part D

Starting January 1, 2025, Medicare Part D enrollees benefit from a hard cap of $2,000 on total out-of-pocket prescription drug spending per year. This is arguably the most broadly impactful provision of the IRA for Medicare beneficiaries, because it protects against catastrophic drug costs regardless of which medications you take.

Before this cap, Medicare Part D had a coverage structure often called the "donut hole," where patients could face significant cost-sharing after their drug spending exceeded an initial threshold but before catastrophic coverage kicked in. Under the old structure, patients with expensive medications could face annual out-of-pocket costs of $5,000, $10,000, or more. The $2,000 cap eliminates this exposure entirely.

The cap applies to all out-of-pocket costs including deductibles, copays, and coinsurance. Once you hit $2,000 in total out-of-pocket spending for the year, your Part D plan covers the full cost of your medications for the remainder of the year. Medicare also offers the Medicare Prescription Payment Plan, which allows enrollees to spread their out-of-pocket costs into predictable monthly payments throughout the year rather than facing large bills during the months when they fill expensive prescriptions.

Inflation Rebates: Keeping Prices in Check

A lesser-known but important provision of the IRA requires drug manufacturers to pay rebates to Medicare if they raise their drug prices faster than the rate of inflation. This provision, which took effect in 2023, applies to both Part B (drugs administered in medical settings) and Part D (pharmacy drugs). If a manufacturer raises the price of a drug above the inflation rate (measured by the Consumer Price Index for Urban Consumers), they must pay the difference back to Medicare.

This provision does not directly lower prices that patients see at the pharmacy, but it acts as a powerful disincentive for manufacturers to continue the annual price increases of 5%, 8%, or 10% that were common before the IRA. Several major pharmaceutical companies have moderated their price increases in response, keeping annual increases closer to the inflation rate. Over time, this restraint compounds, because each year's price becomes the new baseline. A drug that might have risen from $500 to $700 over five years under the old system might now rise only from $500 to $550.

What's Coming: The Timeline Through 2029

The IRA's drug pricing provisions are being phased in over several years. The first ten drugs had their negotiated prices take effect in 2026. An additional 15 drugs will have negotiated prices effective in 2027, including both Part D and Part B drugs. Up to 15 more Part B and Part D drugs will be added for 2028, and another 20 for 2029. By the end of the decade, Medicare will be negotiating prices for as many as 60 high-cost drugs, covering a significant share of total Medicare drug spending.

The selection criteria prioritize drugs that account for the highest Medicare spending and that have been on the market long enough that their patent exclusivity periods have ended, meaning their manufacturers have already had ample time to recoup their research and development investments. This means the program targets exactly the drugs where high prices are hardest to justify: older brand-name medications without generic competition.

What This Means If You Are Not on Medicare

If you have commercial insurance, an employer plan, or no insurance at all, the IRA's direct provisions do not apply to you. You will not see the negotiated prices at your pharmacy, and the $2,000 cap does not cover your spending. This is the most significant limitation of the law, and it means that tens of millions of Americans under 65 continue to face unregulated drug prices.

That said, there are indirect effects. The inflation rebate provision may slow the rate of price increases across the market, not just for Medicare. Some manufacturers have reduced list prices for all payers in response to the political pressure created by the IRA negotiations. And the $35 insulin cap, while legally applicable only to Medicare, prompted voluntary price reductions from insulin manufacturers that benefit all patients.

For non-Medicare patients, the best strategy remains the same: compare prices across pharmacies and discount programs, use manufacturer copay cards when available, apply for patient assistance programs if you qualify, and always ask whether a cheaper alternative exists. RxGator can help with the comparison step, showing you prices from multiple sources so you can find the lowest available price for your specific medication.